Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.45 |
| ▸ | BACE1 | P56817 | 5/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 4/20 | 0.41 |
| ▸ | BCHE | P06276 | 3/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289865 | 0.89 | LTA4H (0.45) | ACHEBACE1LTA4HDRD4BCHE | |
| SCHEMBL4290290 | 0.88 | ACHE (0.45) | ACHEBACE1LTA4HDRD4BCHE | |
| SCHEMBL4284730 | 0.88 | ACHE (0.46) | ACHEBACE1LTA4HMKNK1DRD4 | |
| SCHEMBL4295880 | 0.86 | MEN1 (0.49) | ACHEBACE1LTA4HDRD4BCHE | |
| SCHEMBL4282272 | 0.85 | LTA4H (0.48) | ACHEBACE1LTA4HDRD4DRD2 | |
| SCHEMBL4294444 | 0.85 | ACHE (0.48) | ACHEBACE1LTA4HDRD4BCHE | |
| SCHEMBL4291279 | 0.85 | ACHE (0.46) | ACHEBACE1LTA4HDRD4BCHE | |
| SCHEMBL4286385 | 0.84 | TSHR (0.49) | ACHEBACE1LTA4HDRD4BCHE | |
| SCHEMBL4422792 | 0.83 | LTA4H (0.48) | ACHEBACE1LTA4HDRD4DRD2 | |
| SCHEMBL4292501 | 0.83 | LTA4H (0.48) | ACHEBACE1LTA4HDRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | ACHE 698/4885BACE1 1003/4885LTA4H 1197/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | ACHE 698/4885BACE1 1003/4885LTA4H 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.